Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Trading 08-05 14:49:52 EDT

195.72

+2.26

+1.17%

High198.30	Low192.56	Vol1.02M
Open194.10	D1 Closing193.46	Amplitude2.96%
Mkt Cap41.61B	Tradable Cap39.23B	Total Shares212.59M
T/O199.29M	T/O Rate0.51%	Tradable Shares200.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":195.72,"timestamp":1785955791714,"preClose":193.46,"halted":0,"volume":1017926,"delay":0,"changeRate":0.011682001447327565,"floatShares":200428539,"shares":212592561,"eps":-7.121384,"marketStatus":"Trading","change":2.26,"latestTime":"08-05 14:49:52 EDT","open":194.1,"high":198.295,"low":192.5601,"amount":199290285.18672,"amplitude":0.029644,"askPrice":195.83,"askSize":105,"bidPrice":195.74,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-7.121384,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785960000000},"marketStatusCode":2,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":193.46,"preHourTrading":{"tag":"盘前","latestPrice":193.75,"preClose":193.46,"latestTime":"09:15 EDT","volume":958,"amount":185747.70254,"timestamp":1785935706308,"change":0.29,"changeRate":0.001499,"amplitude":0.015404},"postHourTrading":{"tag":"盘后","latestPrice":191.2852,"preClose":193.46,"latestTime":"19:43 EDT","volume":37616,"amount":7271381.922,"timestamp":1785887020205,"change":-2.1748,"changeRate":-0.011242,"amplitude":0.013336},"volumeRatio":0.686179,"impliedVol":0.5753,"impliedVolPercentile":0.5697},"requestUrl":"/m/hq/s/RVMD/tweets","defaultTab":"tweets","newsList":[{"id":"1100087933","title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1100087933","media":"Market Focus","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100087933?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:35","pubTimestamp":1785861339,"startTime":"0","endTime":"0","summary":"On August 5, Revolution Medicines, Inc. rose 5.23% in regular trading, trading near $191.85/share, with turnover of approximately $105 million.On the news front, multiple catalysts converged to drive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588975","title":"Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588975","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588975?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:55","pubTimestamp":1785801305,"startTime":"0","endTime":"0","summary":"Revolution Medicines Inc <RVMD.OQ> expected to post a loss of $1.98 a share - Earnings PreviewRevolution Medicines IncRVMD.OQRVMD.Ois expected to  show a rise in quarterly revenue when it reports  res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","CANC","IDNA","BBH","IE0002141913.USD","IE00BJJMRZ35.SGD","RVMD","PTH","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE0009354923.USD","LU0320765992.SGD","BK4139","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656252843","title":"Jefferies Cuts Ipsen to 'underperform' on Somatuline Competition Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2656252843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656252843?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:00","pubTimestamp":1785740403,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk** Jefferies downgrades French pharma firm IpsenIPN.PAto \"underperform\" from \"neutral,\" citing  long-term risks to its Somatul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL6N4400DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","IDNA","IE00BFTCPJ56.SGD","LU0109394709.USD","CANC","IE0002141913.USD","IE00BJJMRZ35.SGD","RVMD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0009354923.USD","BK4139","PTH","BBH","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655736076","title":"FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655736076","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655736076?lang=en_us&edition=fundamental","pubTime":"2026-07-31 23:13","pubTimestamp":1785510787,"startTime":"0","endTime":"0","summary":"Revolution Medicines announced that the FDA has accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma, supported by the positive Phase 3 RASolute 302 trial showing improved survival, progression-free survival and quality of life versus standard chemotherapy.\nThe therapy’s inclusion in multiple high-priority U.S. and European regulatory programs, including the FDA...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/fda-priority-review-for-daraxonrasib-might-change-the-case-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/fda-priority-review-for-daraxonrasib-might-change-the-case-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTH","LU1861219969.SGD","LU2357305700.SGD","IE00B2B36J28.USD","BK4585","LU0724618433.USD","LU0889565916.HKD","IE0002141913.USD","LU2360107325.USD","IE00BFMHRM44.USD","BBH","IE00B4R5TH58.HKD","LU1978683503.SGD","BK4141","LU0348723411.USD","LU1983260115.SGD","LU1720051108.HKD","BK4512","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0009354923.USD","CANC","LU1861220033.SGD","LU1720051017.SGD","LU2298322129.HKD","IDNA","ON","IE0009355771.USD","LU1854103824.USD","BK4139","LU0109394709.USD","RVMD","IE00BD6J9T35.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4605","LU1861214812.USD","LU0124384867.USD","LU1861215975.USD","BK4588","IE00BZ199S13.USD","LU1548497426.USD","LABU","LU1854104046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196225378","title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1196225378","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196225378?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:13","pubTimestamp":1785438803,"startTime":"0","endTime":"0","summary":"On July 31, Revolution Medicines, Inc. rose 5.02% in regular trading, trading at $190.0/share, with turnover of $230 million.On the news front, the FDA formally accepted the company's New Drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655195008","title":"Revolution Medicines to Report Q2 Financial Results After Market Close, Hosts Webcast Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655195008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655195008?lang=en_us&edition=fundamental","pubTime":"2026-07-30 04:19","pubTimestamp":1785356352,"startTime":"0","endTime":"0","summary":"Revolution Medicines to report Q2 financial results after market close, hosts webcast updateRevolution Medicines schedules Q2 2026 financial results release for Aug. 5, 2026, following the market clos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL1RwLL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","LU0314104364.USD","BK4112","PTH","SG9999014005.SGD","CANC","LU2210150020.SGD","SG9999014039.USD","NDAQ","BK4139","IE00B64PRP62.GBP","BCDF","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE0009355771.USD","LU2095319765.USD","IE0002141913.USD","IE00BN0W2W23.USD","LU0889565916.HKD","LU2210149790.SGD","BK4588","IE00BJJMRZ35.SGD","RVMD","BK4585","IE00BJT1NW94.SGD","BBH","IDNA","IE00BN0W2V16.EUR","SG9999014021.USD","IE00B2B36J28.USD","IE0009354923.USD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770581","title":"Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770581","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653770581?lang=en_us&edition=fundamental","pubTime":"2026-07-24 11:33","pubTimestamp":1784864028,"startTime":"0","endTime":"0","summary":"Revolution Medicines previously announced that the U.S. FDA accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic ductal adenocarcinoma, supported by Phase 3 RASolute 302 data showing improved overall and progression-free survival versus standard chemotherapy.\nThe drug’s Breakthrough Therapy and Orphan Drug designations, together with inclusion in the FDA Commissioner’s National Priority Voucher...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-is-up-53-after-fda-priority-review","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/revolution-medicines-rvmd-is-up-53-after-fda-priority-review","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","BK4588","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","ON","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2298322129.HKD","LU1854104046.USD","IE0009354923.USD","LU1861214812.USD","RVMD","LU1983260115.SGD","LU1861219969.SGD","BK4512","LU2360107325.USD","LU2357305700.SGD","BK4139","LABU","PTH","IE00BZ199S13.USD","LU1854103824.USD","IE00BFMHRM44.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4141","IDNA","IE00BD6J9T35.USD","LU0124384867.USD","LU0109394709.USD","LU1548497426.USD","LU0348723411.USD","BBH","BK4605","LU1720051108.HKD","LU1861215975.USD","CANC","LU0889565916.HKD","BK4585","LU0724618433.USD","LU1861220033.SGD","LU1720051017.SGD","LU1978683503.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653729886","title":"Revolution Medicines is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2653729886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653729886?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:33","pubTimestamp":1784817180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings(END) Dow Jones NewswiresJuly 23, 2026 10:33 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115892068","title":"Movement Alert｜Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1115892068","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115892068?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:25","pubTimestamp":1784816721,"startTime":"0","endTime":"0","summary":"On July 23, Revolution Medicines, Inc. rose 5.06% in regular trading, trading at $192.03/share, with turnover of $106 million.On the news front, the FDA formally accepted the company's New Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653441367","title":"Revolution Medicines Inc : Wedbush Raises Target Price to $192.1 from $181","url":"https://stock-news.laohu8.com/highlight/detail?id=2653441367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653441367?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:13","pubTimestamp":1784805194,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43P0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","CANC","IE0002141913.USD","IDNA","IE0009355771.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE0009354923.USD","LU0320765992.SGD","RVMD","BBH","PTH","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653604741","title":"Wedbush Raises Price Target on Revolution Medicines to $192.10 From $181, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2653604741","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653604741?lang=en_us&edition=fundamental","pubTime":"2026-07-23 18:56","pubTimestamp":1784804173,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $203.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653993447","title":"Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2653993447","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653993447?lang=en_us&edition=fundamental","pubTime":"2026-07-23 05:35","pubTimestamp":1784756119,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, retaining the price target of $263.00. Charles Zhu has give...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/regulatory-momentum-for-daraxonrasib-and-ras-pipeline-upside-support-charles-zhus-buy-rating-on-rvmd-with-unchanged-263-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/regulatory-momentum-for-daraxonrasib-and-ras-pipeline-upside-support-charles-zhus-buy-rating-on-rvmd-with-unchanged-263-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653796206","title":"Revolution Medicines receives FDA review acceptance for daraxonrasib","url":"https://stock-news.laohu8.com/highlight/detail?id=2653796206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653796206?lang=en_us&edition=fundamental","pubTime":"2026-07-23 05:05","pubTimestamp":1784754334,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the U.S. Food and Drug Administration accepted for review the company’s new drug application for daraxon...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-receives-fda-review-acceptance-for-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-receives-fda-review-acceptance-for-daraxonrasib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","IDNA","BBH","LU0889565916.HKD","IE00B4R5TH58.HKD","PTH","BK4139","RVMD","IE0009354923.USD","LABU","IE0002141913.USD","LU0320765992.SGD","BK4585","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0009355771.USD","CANC","IE00BJT1NW94.SGD","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653798724","title":"Revolution Medicines Says FDA Accepts Daraxonrasib NDA for Previously Treated Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653798724","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653798724?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:11","pubTimestamp":1784751111,"startTime":"0","endTime":"0","summary":"Revolution Medicines says FDA accepts daraxonrasib NDA for previously treated metastatic pancreatic cancerRevolution Medicines’ NDA for daraxonrasib in previously treated metastatic pancreatic ductal ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL71TRHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK4585","IDNA","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD","SG9999014013.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE0009355771.USD","PTH","SG9999014021.USD","IE0009354923.USD","LU0109394709.USD","IE00BKPKM429.USD","IE00B2B36J28.USD","LU0314104364.USD","RVMD","IE0002141913.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","CANC","BCDF","SG9999014005.SGD","BK4139","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653779866","title":"Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653779866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653779866?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:05","pubTimestamp":1784750700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA1HDNRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CANC","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009354923.USD","LU0889565916.HKD","PTH","BBH","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD","BK4139","RVMD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652976692","title":"Revolution Medicines is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2652976692","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652976692?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:47","pubTimestamp":1784544420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings(END) Dow Jones NewswiresJuly 20, 2026 06:47 ET","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189616395","title":"Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36","url":"https://stock-news.laohu8.com/highlight/detail?id=1189616395","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189616395?lang=en_us&edition=fundamental","pubTime":"2026-07-17 16:33","pubTimestamp":1784277217,"startTime":"0","endTime":"0","summary":"On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.Within the Biotechnology sector where Revolution Medicines belongs, the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651410809","title":"Revolution Medicines Inc : JP Morgan Raises Target Price to $205 from $200","url":"https://stock-news.laohu8.com/highlight/detail?id=2651410809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651410809?lang=en_us&edition=fundamental","pubTime":"2026-07-16 17:04","pubTimestamp":1784192680,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43I0XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0109394709.USD","PTH","IE0002141913.USD","IDNA","CANC","BBH","LU0889565916.HKD","IE00B2B36J28.USD","BK4139","IE0009354923.USD","RVMD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650296159","title":"Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650296159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650296159?lang=en_us&edition=fundamental","pubTime":"2026-07-11 22:30","pubTimestamp":1783780221,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vera-therapeutics-vera-crinetics-pharmaceuticals-crnx-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","CRNX","BK4585","IDNA","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","HCSG","LU0128526141.USD","XLV","LU0029874061.USD","LU0320765992.SGD","BK4581","IE0009355771.USD","BK4137","PTH","VERA","LABU","LU0109394709.USD","IE00B2B36J28.USD","RVMD","IE0002141913.USD","LU2324357040.USD","BK4007","BK4539","CANC","BK4139","BK4588","XBI","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650871071","title":"Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650871071","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650871071?lang=en_us&edition=fundamental","pubTime":"2026-07-10 20:01","pubTimestamp":1783684888,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-alnylam-pharma-alny-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-simulations-plus-slp-alnylam-pharma-alny-and-revolution-medicines-rvmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0320765992.SGD","IE00B4R5TH58.HKD","HCSG","BK4167","RVMD","BK4581","SLP","LU0882574055.USD","ALNY","IE00B2B36J28.USD","LU0128526141.USD","LU0109394709.USD","IE00BJT1NW94.SGD","PBE","LU0889565916.HKD","CANC","BK4548","PTH","XLV","LU0114720955.EUR","BK4139","LU0029874061.USD","BBH","BK4137","BK4588","IDNA","LABU","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4585","IE0002141913.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com;ir.revmed.com","stockEarnings":[{"period":"1week","weight":0.0522},{"period":"1month","weight":0.0223},{"period":"3month","weight":0.2806},{"period":"6month","weight":1.0121},{"period":"1year","weight":4.2033},{"period":"ytd","weight":1.4289}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.034782},{"month":2,"riseRate":0.666667,"avgChangeRate":0.00452},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.031822},{"month":4,"riseRate":0.714286,"avgChangeRate":0.114077},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.015463},{"month":6,"riseRate":0.857143,"avgChangeRate":0.063598},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.000417},{"month":8,"riseRate":0.714286,"avgChangeRate":0.055901},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027192}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction